SYNERGIC-2 is the first large Canadian clinical trial using a 12-month home-based personalized multidomain lifestyle intervention to improve cognition in 550 older adults with Mild Cognitive Impairment (MCI), a pre-dementia state. This personalized intervention targets 5 domains, including physical exercise, cognitive training, diet recommendations, sleep interventions, and vascular risk factor management, which are all delivered using a digital platform. This will be compared to the effects of an online educational program. Both interventions are part of the Canadian Dementia Research Strategy.

Studies on early detection of heart disease in young high-risk women with and without PCOS are limited. Polycystic ovary syndrome (PCOS) is the most common hormone-metabolic disorder in women and they are at increased risk of heart disease. Those with PCOS often have infertility, menstrual dysfunction and elevated testosterone levels, and altered metabolism, obesity, diabetes and high blood pressure. We will measure early markers of heart disease at baseline and then at 2yrs follow up including blood fats, heart function and vascular disease in women with and without PCOS with the same age and body weight. The outcomes of this study will help us understand early signs and progression of heart disease in women.

Oxygen (O2) can be both lifesaving and toxic. All ICU patients receiving mechanical ventilation receive O2 therapy. Clinicians are more concerned about a life-threatening lack of O2, termed hypoxia. Accruing evidence now shows that excess O2 exposure, termed hyperoxia, can also cause harm. The adverse effects of hyperoxia may not be immediate. Alberta data show >80% of ICU patients are exposed to hyperoxia. Accordingly, in a clinical trial we are comparing 2 strategies for O2 therapy in ICU patients receiving mechanical ventilation on mortality: usual (liberal) O2 targets vs conservative O2 targets. We are conducting this trial in multiple countries and an to enroll 40,000 critically ill patients.

This registry is for patients who have been diagnosed with an acute aortic dissection/intramural hematoma (also known as a DeBakey I or Stanford type A dissection/intramural hematoma) and have had the Ascyrus Medical Dissection Stent (AMDS) device implanted. The purpose of this registry is to collect additional information of the AMDS following market approval. If the AMDS device, together with conventional surgery is effective, it is believed that this could lead to a cure of the dissection (tear) in the aorta, reduced hospitalizations, and decreased risk of additional aorta surgeries in the chest compared to conventional surgery alone.

The purpose of this study is to find out whether BI 690517 (investigational drug) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: - BI 690517 and empagliflozin - Placebo and empagliflozin

Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is a short tripeptide IRW (made of three amino acids). This is a feasibility study designed to assess the acute effect of IRW for the management of high sugar and blood pressure. Participants will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing a protein powder. Each treatment will be separated by a minimum of 1-week. Participants in the healthy control group will undergo 1 treatment only (one day).

The purpose of this study is to learn whether there are changes in the blood in stroke that can be used as biomarkers to aid in stroke diagnosis, and provide insight to the biology of stroke. Molecules in the blood are being assessed in patients with stroke and compared to persons who are healthy or who have other medical or neurological diseases that mimic stroke. The goal is to see if we can improve stroke diagnosis using a person’s blood, and gain insight to changes in the blood that could improve stroke treatment and prevention.

We want to understand why spasticity develops in cerebral palsy. Spasticity is involuntary contractions that make voluntary contractions more difficult. Spasticity may also produced stiffer muscles. We are examining if the neurons in the spinal cord respond to inputs from the brain differently compared to typically developing children and when during development may this occur. This information will help us to develop new treatment strategies for spasticity in cerebral palsy.

Vaping has become common in Canada. There is little information regarding its safety despite its wide use. We will test how two sessions of vaping affects inflammation in the lung. We will test people who vape regularly and those who have never vaped to see if the lung inflammation is different between these groups. We will avoid vaping liquids that have nicotine in them since that is highly addictive.

WCHRI is collaborating with the Healthy Infants and Children’s Clinical Research Program (HICCUP) to develop a registry of healthy children and families in Alberta who are willing to take part in pediatric health studies. Healthy participants play an important role in health research and the discovery of the causes and treatment of childhood illnesses. HICCUP provides: - researchers and investigators with ready, systematic access to healthy controls for their studies. - participants with a sense of pride in knowing that they have positively contributed to child and community health in Alberta.